EUVIMEDEUVIMED entdecken
Crossref

Effect of the IDH1 inhibitor combined with hypomethylating agents on acute myeloid leukemia

Yan Cheng iD, Hongwei Wu

Tumori Journal · 2025

DOI: 10.1177/03008916251346563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tumori Journal, 2025. Verfasst von Yan Cheng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Leukemia, Myeloid, Acute, Glycine, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Effect of IDH1 inhibitor combined with demethylation drugs on acute myeloid leukemia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) occur in approximately 6-10% of acute myeloid leukemia (AML) patients. Ivosidenib (IVO) is a small-molecule inhibitor of mutant IDH1. This study delves into the mechanism of IVO with hypomethylating agents (HMAs) (azacitidine or decitabine) for treating IDH1-mutated AML through the PI3K/AKT pathway.

Methods

IDH1 R132H -mutated MOLM-13 (IDH1 R132H -MOLM-13) cells were constructed. The effects of the drugs, both individually and in combination, on IDH1 R132H -MOLM-13 cell proliferation and apoptosis were assessed using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide and flow cytometry, with combination index (CI) values calculated using CompuSyn software. IDH1 , DNMT1 , PI3K and AKT gene mRNA levels, and the PI3K/AKT pathway- and histone lysine methylation-related protein levels in IDH1 R132H -MOLM-13 cells were determined by RT-qPCR and Western blot.

Results

IDH1 R132H -mutated MOLM-13 cells (IDH1 R132H -MOLM-13) were successfully constructed. The IDH1 inhibitor, either as a monotherapy or combined with HMAs, effectively inhibited IDH1 R132H -MOLM-13 cell proliferation, and the combination therapy exhibited synergistic effects (CI < 1). The combination therapy increased cell proportion in the G2/M phase and apoptotic rate. Both treatment modalities reduced IDH1 , DNMT1 , PI3K and AKT mRNA levels and histone lysine methylation levels (H3K4me3, H3K9me3, H3K27me3); besides, PI3K and AKT phosphorylation levels were reduced, with the reductions being more significant in cells undergoing combination therapy. The indexes did not differ significantly between cells undergoing the two modalities of combined treatments.

Conclusion

The IDH1 inhibitor with HMAs suppressed IDH1 R132H -MOLM-13 cell proliferation and viability and decreased the methylation level by repressing the phosphorylation of the PI3K/AKT pathway, showing a synergistic inhibitory effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseLeukemia, Myeloid, AcuteGlycineAntineoplastic Combined Chemotherapy ProtocolsHumansCell ProliferationApoptosisCell Line, TumorDecitabineAzacitidineProto-Oncogene Proteins c-aktMutationSignal TransductionPhosphatidylinositol 3-KinasesPyridinesDNA MethylationEnzyme InhibitorsDrug Synergism

Stichwörter der Autor:innen

Acute myeloid leukemiaapoptosisazacitidinedecitabinedemethylationisocitrate dehydrogenase 1 inhibitor ivosidenib

Substanzen

Isocitrate DehydrogenaseIDH1 protein, humanDecitabineAzacitidineProto-Oncogene Proteins c-aktivosidenibGlycinePhosphatidylinositol 3-KinasesPyridinesEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China.

ORCID-Profile: Yan Cheng

Förderung

  • Effect of IDH1 inhibitor combined with demethylation drugs on acute myeloid leukemia

Zitieren

APA

Cheng, Y., & Wu, H. (2025). Effect of the IDH1 inhibitor combined with hypomethylating agents on acute myeloid leukemia. Tumori Journal. https://doi.org/10.1177/03008916251346563

Vancouver

Cheng Y, Wu H. Effect of the IDH1 inhibitor combined with hypomethylating agents on acute myeloid leukemia. Tumori Journal. 2025. doi:10.1177/03008916251346563

BibTeX
@article{Cheng2025,
  author = {Cheng, Yan and Wu, Hongwei},
  title = {Effect of the IDH1 inhibitor combined with hypomethylating agents on acute myeloid leukemia},
  journal = {Tumori Journal},
  year = {2025},
  doi = {10.1177/03008916251346563}
}
Kostenlos starten →